Standardized efficacy and safety evaluation of fulranumab for osteoarthritis

To assess the impact of fulranumab intervention on osteoarthritis (OA) patients and offer a clinically relevant, evidence-based guide for fulranumab intervention in patients with OA. RevMan 5.4 was utilized to conduct a meta-analysis after relevant data on randomized controlled trials of therapeutic interventions for patients with OA were gathered from literature databases such PubMed, Embase, Web of Science, and the Cochrane Library. A total of 8 randomized controlled studies were included, including 1927 patients with osteoarthritis. Meta-analysis showed that compared with the control group, fulranumab intervention had more gains, (MD = - 6.76, 95% CI [- 13.37 to - 0.15]; Z = 2.00; P = 0.05), WOMAC pain (3 mg, week 17) (MD = - 0.78, 95% CI [- 1.10 to - 0.46]; Z = 4.79; P < 0.00001), BPI-SF: pain intensity score (1 mg, week 12) (MD = - 4.29, 95% CI [- 9.15 to 0.57]; Z = 1.73; P = 0.08), and BPI-SF: pain interference (1 mg, week 12) (MD = - 5.98, 95% CI [- 6.64 to - 5.32]; Z = 17.84; P < 0.00001). When used in conjunction with nerve growth factor (NGF) therapy, fulranumab offers an efficient osteoarthritis therapeutic alternative. Patients with osteoarthritis can have a considerable improvement in their WOMAC, short pain inventory, patient global assessment scores, clinical symptoms, and overall quality of life. One possible therapeutic approach for the condition might be to use fulranumab.